Compare YSG & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | HELP |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | Canada |
| Employees | N/A | 50 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.5M | 279.9M |
| IPO Year | 2020 | N/A |
| Metric | YSG | HELP |
|---|---|---|
| Price | $2.80 | $4.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 109.3K | ★ 1.4M |
| Earning Date | 05-15-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $4.29 |
| 52 Week High | $11.04 | $8.55 |
| Indicator | YSG | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 42.75 |
| Support Level | N/A | $4.55 |
| Resistance Level | $3.36 | $8.55 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 22.22 | 7.81 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.